title: [Irbesartan reduces inflammatory response of central nervous system in a rat model of fluid percussion brain injury].
abstract: Objective To investigate the neuroprotective effect of the angiotensin II receptor 1 (AT1) antagonist irbesartan on rat models with lateral fluid percussion brain injury (FPBI). Methods FPBI models were prepared using a modified fluid percussion injury method. Before and after modeling, irbesartan was given to the rats. The regional cerebral blood flow (rCBF) was monitored by laser Doppler flowmetry. Neurologic status was evaluated before and 1, 3, 5, 7 days after FPBI surgery. Brains were removed for immunohistochemical evaluation of active microglias and macrophages. Results Compared to sham group, the rCBF and neurologic score of FPBI rats decreased significantly, while microglia and macrophage activation were confirmed. Treatment with irbesartan before FPBI surgery increased rCBF and improved neurological functions. In the peri-infarct cortex, irbesartan treatment attenuated the invasion of activated microglias and macrophages on day 7 after FPBI surgery. Conclusion Irbesartan can play a neuroprotective role through inhibiting microglia and macrophage activation in FPBI rats.
authors.affiliation: Department of Neurosurgery, Urumqi General Hospital, Lanzhou Military Area Command, Urumqi 830000, China.
authors.forename: Guoxiang
authors.initials: G
authors.lastname: Xing
authors.affiliation: Lintong Sanatorium of Lanzhou Military Area Command, Lintong 710600, China.
authors.forename: Min
authors.initials: M
authors.lastname: Wei
authors.affiliation: Department of Neurosurgery, Urumqi General Hospital, Lanzhou Military Area Command, Urumqi 830000, China.
authors.forename: Binhua
authors.initials: B
authors.lastname: Xiu
authors.affiliation: Department of Neurosurgery, Urumqi General Hospital, Lanzhou Military Area Command, Urumqi 830000, China.
authors.forename: Yinghui
authors.initials: Y
authors.lastname: Ma
authors.affiliation: Office of Clinical Administration, Fourth Military Medical University, Xi'an 710032, China. *Corresponding author, E-mail: liutao66@fmmu.edu.cn.
authors.forename: Tao
authors.initials: T
authors.lastname: Liu
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology*; D001921:Brain / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D001930:Brain Injuries / Q000503:physiopathology / Q000517:prevention & control*; D002245:Carbon Dioxide / Q000097:blood; D002493:Central Nervous System Diseases / Q000503:physiopathology / Q000517:prevention & control*; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004195:Disease Models, Animal; D007249:Inflammation / Q000503:physiopathology / Q000517:prevention & control*; D000077405:Irbesartan; D008262:Macrophage Activation / Q000187:drug effects; D008297:Male; D017628:Microglia / Q000187:drug effects / Q000473:pathology; D018696:Neuroprotective Agents / Q000494:pharmacology; D010100:Oxygen / Q000097:blood; D011312:Pressure; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow / Q000187:drug effects; D013777:Tetrazoles / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D018696:Neuroprotective Agents; D013777:Tetrazoles; D002245:Carbon Dioxide; D000077405:Irbesartan; D010100:Oxygen